Hikma Pharmaceuticals PLC : Still a great upward potential
Entry price | Target | Stop-loss | Potential |
---|
GBX 1,273 |
GBX 0 |
GBX 1,218 |
-100% |
---|
The GBp 1313 resistance is in line of sight.
The company’s fundamentals are still strong. Sales are expected to be up by 20.6% for one year. Analysts from Thomson Reuters consensus have revised largely upward their EPS estimates during the year. The revenue anticipations have been revised as well all over the year.
Technically, the security shows a bullish configuration on all time scales. Prices are supported by increasing moving averages. In daily data, 20-day moving average helps the stock to keep its uptrend and to reach the first resistance at GBp 1315. By extension the GBp 1400 can be reached
Traders can buy the stock with a target price at GBp 1315 and then GBp 1400 (swing effect) with a stop-loss around GBp 1220.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.